0000000000374804

AUTHOR

G. Formoso

showing 3 related works from this author

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

2020

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy. We included 2484 patients who were initiated on dapagliflozin in 2015–2016 and 14,801 patients who were initiated on other GLM (DPP-4 inhibitors, GLP-1 receptor agonists, or gliclazide) in the same period. After excluding patients who had no…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesDiabetes mellitusInternal medicineAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetes; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding TreatmentDiabetes MellitusmedicineHumansHypoglycemic AgentsOutpatient clinicBenzhydryl CompoundsDapagliflozinObservationalAgedRetrospective StudiesDipeptidyl-Peptidase IV InhibitorsAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetesbusiness.industryType 2 diabetesRetrospective cohort studyMiddle Agedmedicine.diseasePharmacotherapyMetforminDiscontinuationDiabetes Mellitus Type 2Real-worldWithholding TreatmentchemistryTolerabilityAdherence030220 oncology & carcinogenesisFemalebusinessType 2medicine.drugJournal of Endocrinological Investigation
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly)…

2011

In 2007 the Italian COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) study group started to assess the application in a clinical setting of the Versailles criteria for management of acromegaly complications by a first questionnaire focusing on cardiovascular co-morbidities. A further questionnaire on sleep apnea syndrome (SAS) was delivered by the COM.E.T.A. study group to 107 endocrine centers in Italy. The results of our survey suggest that SAS is a well-known comorbidity even if its estimated prevalence is lower than in the literature. Polysomnography is the preferred tool for diagnosis. Control of SAS is considered relevant both for quality of life and co-morbidities. C…

MalePediatricsmedicine.medical_specialtymedicine.medical_treatmentEndocrinology Diabetes and MetabolismPolysomnographyPolysomnographyComorbiditysomatostatin analogs; acromegaly; sleep apnea syndromeSettore MED/13 - EndocrinologiaSomatostatin analogEndocrinologySleep Apnea SyndromesQuality of lifeAcromegaly; Sleep apnea syndrome; Somatostatin analogs;PhysiciansSurveys and QuestionnairesAcromegalymedicinePrevalenceHumansContinuous positive airway pressuremedicine.diagnostic_testbusiness.industrySleep apneaAwarenessFocus Groupssleep apneamedicine.diseaseComorbidityAcromegaly; Sleep apnea syndrome; Somatostatin analogsAcromegaly; Sleep ApneaSleep apnea syndromeItalySomatostatin analogsAcromegalyPhysical therapyCOM.E.TA.FemaleClinical Competencebusiness
researchProduct